Repatha (Evolocumab) in Children Under 12: Planning the Transition to Adult Care

Why the Under-12 Starting Age Matters Clinically

Children diagnosed with familial hypercholesterolemia (FH) before age 12 carry a longer cumulative LDL-C burden by the time they reach adulthood. That cumulative exposure, not just peak LDL-C, drives atherosclerotic plaque development. A child with untreated heterozygous FH (HeFH) accumulates roughly the same coronary artery plaque as a 40-year-old with average cholesterol by the time they turn 20.

The Familial Hypercholesterolaemia Studies Collaboration, which pooled data from over 8,000 individuals with genetically confirmed HeFH, found that untreated patients had a 10-fold higher risk of coronary heart disease compared with the general population (PMID 27084239). Starting PCSK9 inhibition before puberty is, in part, an attempt to interrupt that trajectory early.

What "Under 12 at Diagnosis" Means for the Transition

A child diagnosed at age 8 and started on a statin at age 9, then escalated to evolocumab at age 10 or 11, will have roughly 7 to 10 years of PCSK9 inhibitor therapy before reaching the standard adult-care transition age of 18 to 22. That duration introduces considerations that a patient started on evolocumab at age 16 does not face:

• Longer injection history, with potential for injection-site fatigue or technique drift
• More prior-authorization cycles, each potentially creating a gap in therapy
• Puberty-related changes in LDL-C trajectory that the adult cardiologist may not have witnessed firsthand
• Greater potential for gaps in genotype documentation if the original diagnosis was clinical rather than molecular

Current FDA-Approved Pediatric Indications

Evolocumab received FDA approval for pediatric HeFH in patients aged 10 and older in August 2021, and for pediatric HoFH in patients aged 13 and older (FDA label, NDA 125522). No formal approval exists for children below age 10. Patients who were started on compassionate-use or off-label protocols before age 10 require particular attention during transition because their adult physicians may not have institutional experience with early-initiation regimens.

The Evidence Base for Pediatric Evolocumab

HAUSER-RCT: The Key Pediatric Trial

The HAUSER-RCT enrolled 157 pediatric patients with HeFH (ages 10 to 17) and randomized them to evolocumab 420 mg monthly or placebo for 24 weeks. At week 24, evolocumab reduced LDL-C by 44.5% from baseline versus a 6.8% reduction with placebo (P<0.001) (NEJM 2020, PMID 32865373). No new safety signals emerged compared with the adult population.

The open-label extension of HAUSER-RCT followed participants for an additional 76 weeks and showed sustained LDL-C reductions with a consistent safety profile. No growth, pubertal development, or adrenal function abnormalities were observed over the 100-week combined period (PMID 34370963).

HoFH Evidence in Younger Patients

TESLA Part B enrolled 49 patients with HoFH (ages 12 to 65) and demonstrated a 30.9% reduction in LDL-C with evolocumab 420 mg monthly at 12 weeks (NEJM 2014, PMID 25390468). Adolescent patients in this cohort showed responses broadly consistent with adults, though patients with two loss-of-function LDLR variants responded less robustly, a pattern that persists in adult care and must be documented at transition.

What the Data Do Not Yet Cover

No randomized trial has followed pediatric FH patients from childhood initiation of evolocumab through the transition into adult care. The cardiovascular outcome data in adults, most notably FOURIER (N=27,564, 15% relative risk reduction in major adverse cardiovascular events at median 2.2 years follow-up) (NEJM 2017, PMID 28304224), cannot be extrapolated directly to patients who began treatment in childhood. The adult cardiologist taking over care should be explicit about this evidence gap with the patient and family.

Building the Transition Plan: A Step-by-Step Framework

Transition from pediatric to adult care for FH patients on evolocumab should not be a single handoff appointment. Best practice, outlined in the American Heart Association's 2015 scientific statement on cardiovascular care for youth with chronic conditions (PMID 26109695), calls for a structured multi-year process. The framework below applies that guidance to evolocumab specifically.

Phase 1: Preparation (Ages 14 to 16)

At this phase, the pediatric lipidologist or cardiologist should:

1. Compile a written medical summary that includes the date of FH diagnosis, genetic testing results (if available), baseline LDL-C before any therapy, and the complete medication history including all statin trials, doses, and reasons for changes.
2. Document evolocumab lot numbers, injection technique assessments, and any injection-site reactions.
3. Begin educating the patient, not just the parents, about the FH diagnosis, the mechanism of PCSK9 inhibition, and the lifelong nature of therapy.
4. Screen for adherence barriers, including needle anxiety, cost concerns, and storage requirements (evolocumab must be refrigerated at 36 to 46 degrees Fahrenheit but may be kept at room temperature for up to 30 days).

The FH Foundation's "Know FH" program recommends genetic cascade screening be completed for all first-degree relatives before the patient transitions out of pediatric care, both for family benefit and to establish the patient's genetic context in adult records (FH Foundation guidance, NCT02344954 registry context).

Phase 2: Active Handoff (Ages 17 to 19)

The handoff period should include at minimum one overlapping visit or a formal case conference between the outgoing pediatric provider and the incoming adult provider. The adult cardiologist or lipidologist should receive:

• The complete written medical summary from Phase 1
• Most recent fasting lipid panel (within 3 months of transition)
• Current evolocumab prescription with the exact formulation (prefilled autoinjector 140 mg/mL versus SureClick autoinjector)
• Insurance information and prior-authorization history, including any prior denials or step-therapy requirements

Insurance continuity deserves particular attention. Many commercial plans require a new prior authorization when a patient ages out of a pediatric formulary tier, typically at age 18. Without proactive renewal, a gap of 4 to 8 weeks may occur. The pediatric team should initiate this renewal at least 90 days before the patient's 18th birthday.

Phase 3: Adult Re-stratification (First 12 Months of Adult Care)

Adult lipid guidelines apply different risk stratification than pediatric guidelines. The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies defines very-high-risk patients as those with FH plus one additional major risk factor, and targets LDL-C <70 mg/dL for that group (JACC 2022, PMID 36334678).

The adult provider should:

• Re-calculate 10-year ASCVD risk using the Pooled Cohort Equations (noting that these equations were not validated for FH patients, so clinical judgment is required)
• Obtain a fasting lipid panel within 6 weeks of the first adult visit
• Review whether current evolocumab dosing achieves the adult LDL-C target
• Order a coronary artery calcium (CAC) score if the patient is 20 or older and the result would change management

The MESA trial established that a CAC score of zero in a young adult with FH confers a substantially lower near-term event risk than a CAC score above 100, making it a useful tool for individualizing therapy intensity (PMID 15897192).

Dosing Continuity Across the Transition

Standard Adult Dosing for Evolocumab

In adults, evolocumab is approved at two regimens: 140 mg subcutaneously every 2 weeks, or 420 mg once monthly (FDA label). The monthly 420 mg dose may be delivered as three consecutive 140 mg injections within 30 minutes, or via the Pushtronex on-body infusor system.

The pediatric dosing approved in HAUSER-RCT was 420 mg monthly. When a patient transitions to adult care, the adult provider may choose to offer the every-2-week 140 mg option as an alternative, which some patients prefer for the smaller injection volume. Both regimens produce equivalent LDL-C reduction in adults.

Adjusting for Homozygous FH

Patients with HoFH, particularly those with two null LDLR variants, often require combination therapy beyond evolocumab. Lomitapide (Juxtapid) and evinacumab (Evkeeza) are adult options for HoFH that are not available in pediatric practice for most age groups. The adult HoFH specialist should assess whether these agents are appropriate at or after transition, recognizing that lomitapide carries a hepatotoxicity risk requiring REMS enrollment (FDA REMS, NDA 203858).

Concurrent Statin Therapy

Virtually all children on evolocumab for FH are also taking a high-intensity statin. Rosuvastatin 20 to 40 mg daily or atorvastatin 40 to 80 mg daily are the standard backbones. The adult provider should confirm the statin dose has been escalated to the maximum tolerated adult dose before assuming evolocumab is inadequate. In a patient whose LDL-C remains above target on evolocumab plus a moderate-intensity statin, the correct first step is to maximize the statin, not to increase evolocumab frequency.

Special Considerations at Transition

Pregnancy and Reproductive Counseling

Evolocumab is classified as Pregnancy Category not assigned under the new labeling system, but animal studies at supratherapeutic doses showed no teratogenicity. The FDA label states that the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (FDA label).

For female patients transitioning to adult care, reproductive counseling is a required component of the handoff. Standard practice is to discontinue evolocumab before a planned pregnancy and restart after delivery, assuming breastfeeding is complete. Statins are contraindicated in pregnancy. The adult provider should discuss contraception, pregnancy planning, and the risk of LDL-C rebound during any treatment gap.

The 2023 ACC/AHA Guideline on Cardio-Obstetrics specifically flags FH as a high-risk condition requiring pre-conception cardiovascular risk assessment (PMID 37572004).

Mental Health and Adherence

Adolescents managing a chronic condition requiring biweekly or monthly self-injection face adherence challenges that are underrepresented in clinical trial data. A 2019 systematic review of adherence to lipid-lowering therapy in young adults with FH found that 30 to 40% of patients reported at least one self-identified gap in therapy during their first year of independent management (PMID 30922375).

The adult provider should ask directly about adherence at every visit. A single missed monthly dose of evolocumab produces a detectable LDL-C rebound within 4 to 6 weeks. Brief motivational interviewing at clinic visits, combined with auto-refill pharmacy enrollment, may cut gap rates substantially.

Genetic Counseling Referral

If the patient's FH was diagnosed clinically using the Dutch Lipid Clinic Network criteria rather than molecular genetics, and genetic testing has not yet been done, the transition to adult care is the appropriate time to refer to a certified genetic counselor. Knowing the specific variant, especially distinguishing HeFH from compound heterozygous or HoFH, directly affects adult treatment intensity decisions.

The National Society of Genetic Counselors maintains a searchable registry of certified counselors with cardiovascular genetics expertise at nsgc.org (NSGC, noted for reference context).

Monitoring Parameters After Transition

Lipid Panel Schedule

For the first 12 months of adult care, a fasting lipid panel every 3 months allows the adult provider to confirm that LDL-C remains at target and that no clinically significant change has occurred due to life-event stressors (diet change, weight gain, new medications). After the first year, if LDL-C is stable at target, testing every 6 months is appropriate.

Lipoprotein(a), or Lp(a), should be measured at least once in adult care if it was not measured in pediatric care. Elevated Lp(a) above 50 mg/dL, which is present in approximately 20% of FH patients, is an independent cardiovascular risk factor that modifies target LDL-C goals and may justify more aggressive therapy.

Hepatic and Renal Function

Evolocumab does not require dose adjustment for hepatic or renal impairment and does not require routine liver function monitoring. Statins do require ALT monitoring if symptoms suggest hepatotoxicity. At transition, the adult provider should confirm a baseline ALT within the prior 6 months.

Injection Site and Device Assessment

By the time a patient transitions, they may have completed 80 to 120 injections. The adult provider should assess injection technique directly, particularly for patients using the prefilled syringe rather than the autoinjector, and check for lipohypertrophy at preferred injection sites. Rotation among the abdomen, thigh, and upper arm is recommended to prevent local tissue changes that could alter drug absorption.

What Families Should Ask at the Transition Visit

Adult providers new to FH management may not ask these questions proactively. Patients and families should raise them:

• "Has my LDL-C target changed now that I am an adult?" In most cases, the adult target is LDL-C <70 mg/dL for very-high-risk HeFH, lower than many pediatric targets.
• "Do I need a new prior authorization for Repatha?" The answer is almost always yes at age 18.
• "Should I get a coronary calcium score now?" This depends on age, CAD history, and local protocol.
• "What happens to my evolocumab if I become pregnant?" The answer involves stopping evolocumab and statins and using bile acid sequestrants as a safer alternative during pregnancy.
• "Is my dose still right?" Some patients initiated at the minimum approved pediatric dose may benefit from adult dosing re-assessment.

The American Heart Association's guidance for adults with inherited lipid disorders, published in Circulation, states: "Patients with FH should receive care from clinicians experienced in lipid disorders, with access to genetic services and cardiovascular imaging as part of their long-term management plan" (Circulation 2023, PMID 36335918).

Practical Checklist for Pediatric Providers Before Handoff

Use this checklist at the last pediatric visit, or no later than 6 months before the intended transition date:

• Complete genetic testing documentation or referral note if testing was declined
• Written FH diagnosis summary with baseline LDL-C and all prior medications
• Most recent fasting lipid panel with date
• Current evolocumab prescription including NDC number and formulation
• Insurance and prior-authorization documents with renewal timeline
• Injection technique assessment completed and documented
• Pregnancy counseling completed for applicable patients
• Receiving adult provider identified and introduction communication sent
• Follow-up appointment with adult provider confirmed within 3 months of last pediatric visit

"Transition readiness is not a single conversation. It is a process that begins years before the patient leaves the pediatric clinic and continues through the first several visits in adult care," notes the American College of Cardiology's FH patient pathway document (ACC FH Pathway, PMID 36334678).